Purpose. The phenoxyacetic acid, ethacrynic acid (ECA), has potential
use in glaucoma therapy because it acts to increase aqueous outflow in
vivo and in vitro. In human trabecular meshwork (HTM) cell culture, E
CA acts to change cell shape and attachment effects that have been cor
related with microtubule (MT) alterations and chemical sulfhydryl (SH)
reactivity. To further explore these actions, we evaluated two non-SH
reactive phenoxyacetic acids, indacrinone and ticrynafen, and the MT-
disrupting drug vinblastine. Methods. Excised bovine and porcine eyes
were perfused and outflow facility measured. Calf pulmonary artery end
othelial and HTM cells were grown in culture and cytoskeletal effects
evaluated after drug treatment. Results. Indacrinone, ticrynafen, and
vinblastine all caused an increase in outflow facility. In contrast wi
th ECA, the outflow effects of indacrinone and ticrynafen were not bla
cked by excess cysteine. Although indacrinone and ticrynafen produced
changes in cell shape in vitro, the beta-tubulin staining pattern of t
reated cells was not altered. Vinblastine caused cell shape change and
the expected MT disruption. Conclusions. Phenoxyacetic acids can incr
ease aqueous outflow facility and alter HTM cell shape and attachment
in vitro by a non-SH, non-MT mechanism (which is probably shared also
by ECA). These findings suggest the possibility of a broader class of
glaucoma drugs that may be directed at the HTM. An understanding of th
e cellular target for these drugs has implications both for potential
glaucoma therapy and for the cytoskeletal mechanisms involved in norma
l outflow function.